Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound
Identifieur interne : 005B16 ( Main/Exploration ); précédent : 005B15; suivant : 005B17Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound
Auteurs : Els Keyaerts [Belgique] ; Leen Vijgen [Belgique] ; LUNI CHEN [Suède, République populaire de Chine] ; Piet Maes [Belgique] ; Göran Hedenstierna [Suède] ; Marc Van Ranst [Belgique]Source :
- International journal of infectious diseases [ 1201-9712 ] ; 2004.
Descripteurs français
- KwdFr :
- Animaux, Cellules Vero, Donneur d'oxyde nitrique (pharmacologie), Effet cytopathogène viral (), N-Acétyl-S-nitroso-pénicillamine (pharmacologie), Nitroprussiate (pharmacologie), Pénicillamine (analogues et dérivés), Pénicillamine (pharmacologie), Réplication virale (), Syndrome respiratoire aigu sévère (traitement médicamenteux), Virus du SRAS (croissance et développement).
- MESH :
- analogues et dérivés : Pénicillamine.
- croissance et développement : Virus du SRAS.
- pharmacologie : Donneur d'oxyde nitrique, N-Acétyl-S-nitroso-pénicillamine, Nitroprussiate, Pénicillamine.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Animals, Chlorocebus aethiops, Compounds, Coronavirus, Cytopathogenic Effect, Viral (drug effects), Donor, Human, In vitro, Nitric Oxide Donors (pharmacology), Nitric oxide, Nitroprusside (pharmacology), Penicillamine (analogs & derivatives), Penicillamine (pharmacology), S-Nitroso-N-Acetylpenicillamine (pharmacology), SARS Virus (growth & development), Severe Acute Respiratory Syndrome (drug therapy), Severe acute respiratory syndrome, Vero Cells, Virus Replication (drug effects).
- MESH :
- chemical , analogs & derivatives : Penicillamine.
- chemical , pharmacology : Nitric Oxide Donors, Nitroprusside, Penicillamine, S-Nitroso-N-Acetylpenicillamine.
- drug effects : Cytopathogenic Effect, Viral, Virus Replication.
- drug therapy : Severe Acute Respiratory Syndrome.
- growth & development : SARS Virus.
- Animals, Chlorocebus aethiops, Vero Cells.
Abstract
Introduction: The recent outbreak of severe acute respiratory syndrome (SARS) warrants the search for effective antiviral agents to treat the disease. This study describes the assessment of the antiviral potential of nitric oxide (NO) against SARS coronavirus (SARS-CoV) strain Frankfurt-1 replicating in African Green Monkey (Vero E6) cells. Results: Two organic NO donor compounds, S-nitroso-N-acetylpenicillamine (SNAP) and sodium nitroprusside (SNP), were tested in a broad range of concentrations. The non-nitrosylated form of SNAP, N-acetylpenicillamine (NAP), was included as a control compound in the assay. Antiviral activity was estimated by the inhibition of the SARS-CoV cytopathic effect in Vero E6 cells, determined by a tetrazolium-based colorimetric method. Cytotoxicity of the compounds was tested in parallel. Conclusion: The survival rate of SARS-CoV infected cells was greatly increased by the treatment with SNAP, and the concentration of this compound needed to inhibit the viral cytopathic effect to 50% was 222 μM, with a selectivity index of 3. No anti-SARS-CoV effect could be detected for SNP and NAP.
Url:
Affiliations:
- Belgique, République populaire de Chine, Suède
- East Middle Sweden, Province du Brabant flamand, Svealand
- Louvain, Pékin, Uppsala
- Université d'Uppsala
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000832
- to stream PascalFrancis, to step Curation: 000158
- to stream PascalFrancis, to step Checkpoint: 000826
- to stream Main, to step Merge: 005F77
- to stream Pmc, to step Corpus: 001084
- to stream Pmc, to step Curation: 001084
- to stream Pmc, to step Checkpoint: 001622
- to stream PubMed, to step Corpus: 002C80
- to stream PubMed, to step Curation: 002C80
- to stream PubMed, to step Checkpoint: 002C30
- to stream Ncbi, to step Merge: 000930
- to stream Ncbi, to step Curation: 000930
- to stream Ncbi, to step Checkpoint: 000930
- to stream Main, to step Merge: 005683
- to stream Main, to step Curation: 005B16
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound</title><author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratory of Clinical and Epidemiological Virology, Department of Microbiology & Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratory of Clinical and Epidemiological Virology, Department of Microbiology & Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Luni Chen" sort="Luni Chen" uniqKey="Luni Chen" last="Luni Chen">LUNI CHEN</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Medical Sciences, Clinical Physiology, Uppsala University</s1><s3>SWE</s3><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Suède</country><placeName><settlement type="city">Uppsala</settlement><region nuts="1">Svealand</region><region nuts="1">East Middle Sweden</region></placeName><orgName type="university">Université d'Uppsala</orgName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>General Airforce Hospital of China</s1><s2>Beijing</s2><s3>CHN</s3><sZ>3 aut.</sZ></inist:fA14><country>République populaire de Chine</country><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Maes, Piet" sort="Maes, Piet" uniqKey="Maes P" first="Piet" last="Maes">Piet Maes</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratory of Clinical and Epidemiological Virology, Department of Microbiology & Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Hedenstierna, Goran" sort="Hedenstierna, Goran" uniqKey="Hedenstierna G" first="Göran" last="Hedenstierna">Göran Hedenstierna</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Medical Sciences, Clinical Physiology, Uppsala University</s1><s3>SWE</s3><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Suède</country><placeName><settlement type="city">Uppsala</settlement><region nuts="1">Svealand</region><region nuts="1">East Middle Sweden</region></placeName><orgName type="university">Université d'Uppsala</orgName></affiliation></author><author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratory of Clinical and Epidemiological Virology, Department of Microbiology & Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">04-0428753</idno><date when="2004">2004</date><idno type="stanalyst">PASCAL 04-0428753 INIST</idno><idno type="RBID">Pascal:04-0428753</idno><idno type="wicri:Area/PascalFrancis/Corpus">000832</idno><idno type="wicri:Area/PascalFrancis/Curation">000158</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000826</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000826</idno><idno type="wicri:doubleKey">1201-9712:2004:Keyaerts E:inhibition:of:sars</idno><idno type="wicri:Area/Main/Merge">005F77</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128975</idno><idno type="RBID">PMC:7128975</idno><idno type="wicri:Area/Pmc/Corpus">001084</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001084</idno><idno type="wicri:Area/Pmc/Curation">001084</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001084</idno><idno type="wicri:Area/Pmc/Checkpoint">001622</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001622</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15234326</idno><idno type="wicri:Area/PubMed/Corpus">002C80</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002C80</idno><idno type="wicri:Area/PubMed/Curation">002C80</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002C80</idno><idno type="wicri:Area/PubMed/Checkpoint">002C30</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C30</idno><idno type="wicri:Area/Ncbi/Merge">000930</idno><idno type="wicri:Area/Ncbi/Curation">000930</idno><idno type="wicri:Area/Ncbi/Checkpoint">000930</idno><idno type="wicri:doubleKey">1201-9712:2004:Keyaerts E:inhibition:of:sars</idno><idno type="wicri:Area/Main/Merge">005683</idno><idno type="wicri:Area/Main/Curation">005B16</idno><idno type="wicri:Area/Main/Exploration">005B16</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound</title><author><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratory of Clinical and Epidemiological Virology, Department of Microbiology & Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratory of Clinical and Epidemiological Virology, Department of Microbiology & Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Luni Chen" sort="Luni Chen" uniqKey="Luni Chen" last="Luni Chen">LUNI CHEN</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Medical Sciences, Clinical Physiology, Uppsala University</s1><s3>SWE</s3><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Suède</country><placeName><settlement type="city">Uppsala</settlement><region nuts="1">Svealand</region><region nuts="1">East Middle Sweden</region></placeName><orgName type="university">Université d'Uppsala</orgName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>General Airforce Hospital of China</s1><s2>Beijing</s2><s3>CHN</s3><sZ>3 aut.</sZ></inist:fA14><country>République populaire de Chine</country><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Maes, Piet" sort="Maes, Piet" uniqKey="Maes P" first="Piet" last="Maes">Piet Maes</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratory of Clinical and Epidemiological Virology, Department of Microbiology & Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author><author><name sortKey="Hedenstierna, Goran" sort="Hedenstierna, Goran" uniqKey="Hedenstierna G" first="Göran" last="Hedenstierna">Göran Hedenstierna</name><affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Medical Sciences, Clinical Physiology, Uppsala University</s1><s3>SWE</s3><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Suède</country><placeName><settlement type="city">Uppsala</settlement><region nuts="1">Svealand</region><region nuts="1">East Middle Sweden</region></placeName><orgName type="university">Université d'Uppsala</orgName></affiliation></author><author><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Laboratory of Clinical and Epidemiological Virology, Department of Microbiology & Immunology, Rega Institute for Medical Research, University of Leuven, Minderbroedersstraat 10</s1><s2>3000 Leuven</s2><s3>BEL</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>Belgique</country><placeName><region type="province" nuts="2">Province du Brabant flamand</region><settlement type="city">Louvain</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">International journal of infectious diseases</title><title level="j" type="abbreviated">Int. j. infect. dis.</title><idno type="ISSN">1201-9712</idno><imprint><date when="2004">2004</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">International journal of infectious diseases</title><title level="j" type="abbreviated">Int. j. infect. dis.</title><idno type="ISSN">1201-9712</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Compounds</term><term>Coronavirus</term><term>Cytopathogenic Effect, Viral (drug effects)</term><term>Donor</term><term>Human</term><term>In vitro</term><term>Nitric Oxide Donors (pharmacology)</term><term>Nitric oxide</term><term>Nitroprusside (pharmacology)</term><term>Penicillamine (analogs & derivatives)</term><term>Penicillamine (pharmacology)</term><term>S-Nitroso-N-Acetylpenicillamine (pharmacology)</term><term>SARS Virus (growth & development)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe acute respiratory syndrome</term><term>Vero Cells</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Donneur d'oxyde nitrique (pharmacologie)</term><term>Effet cytopathogène viral ()</term><term>N-Acétyl-S-nitroso-pénicillamine (pharmacologie)</term><term>Nitroprussiate (pharmacologie)</term><term>Pénicillamine (analogues et dérivés)</term><term>Pénicillamine (pharmacologie)</term><term>Réplication virale ()</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Virus du SRAS (croissance et développement)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Penicillamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Nitric Oxide Donors</term><term>Nitroprusside</term><term>Penicillamine</term><term>S-Nitroso-N-Acetylpenicillamine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Pénicillamine</term></keywords><keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cytopathogenic Effect, Viral</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Donneur d'oxyde nitrique</term><term>N-Acétyl-S-nitroso-pénicillamine</term><term>Nitroprussiate</term><term>Pénicillamine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Vero Cells</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Effet cytopathogène viral</term><term>Réplication virale</term><term>Syndrome respiratoire aigu sévère</term><term>In vitro</term><term>Azote monoxyde</term><term>Donneur</term><term>Coronavirus</term><term>Homme</term><term>Composé</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Introduction: The recent outbreak of severe acute respiratory syndrome (SARS) warrants the search for effective antiviral agents to treat the disease. This study describes the assessment of the antiviral potential of nitric oxide (NO) against SARS coronavirus (SARS-CoV) strain Frankfurt-1 replicating in African Green Monkey (Vero E6) cells. Results: Two organic NO donor compounds, S-nitroso-N-acetylpenicillamine (SNAP) and sodium nitroprusside (SNP), were tested in a broad range of concentrations. The non-nitrosylated form of SNAP, N-acetylpenicillamine (NAP), was included as a control compound in the assay. Antiviral activity was estimated by the inhibition of the SARS-CoV cytopathic effect in Vero E6 cells, determined by a tetrazolium-based colorimetric method. Cytotoxicity of the compounds was tested in parallel. Conclusion: The survival rate of SARS-CoV infected cells was greatly increased by the treatment with SNAP, and the concentration of this compound needed to inhibit the viral cytopathic effect to 50% was 222 μM, with a selectivity index of 3. No anti-SARS-CoV effect could be detected for SNP and NAP.</div></front></TEI><affiliations><list><country><li>Belgique</li><li>République populaire de Chine</li><li>Suède</li></country><region><li>East Middle Sweden</li><li>Province du Brabant flamand</li><li>Svealand</li></region><settlement><li>Louvain</li><li>Pékin</li><li>Uppsala</li></settlement><orgName><li>Université d'Uppsala</li></orgName></list><tree><country name="Belgique"><region name="Province du Brabant flamand"><name sortKey="Keyaerts, Els" sort="Keyaerts, Els" uniqKey="Keyaerts E" first="Els" last="Keyaerts">Els Keyaerts</name></region><name sortKey="Maes, Piet" sort="Maes, Piet" uniqKey="Maes P" first="Piet" last="Maes">Piet Maes</name><name sortKey="Van Ranst, Marc" sort="Van Ranst, Marc" uniqKey="Van Ranst M" first="Marc" last="Van Ranst">Marc Van Ranst</name><name sortKey="Vijgen, Leen" sort="Vijgen, Leen" uniqKey="Vijgen L" first="Leen" last="Vijgen">Leen Vijgen</name></country><country name="Suède"><region name="Svealand"><name sortKey="Luni Chen" sort="Luni Chen" uniqKey="Luni Chen" last="Luni Chen">LUNI CHEN</name></region><name sortKey="Hedenstierna, Goran" sort="Hedenstierna, Goran" uniqKey="Hedenstierna G" first="Göran" last="Hedenstierna">Göran Hedenstierna</name></country><country name="République populaire de Chine"><noRegion><name sortKey="Luni Chen" sort="Luni Chen" uniqKey="Luni Chen" last="Luni Chen">LUNI CHEN</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005B16 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005B16 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:04-0428753
|texte= Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound
}}
| This area was generated with Dilib version V0.6.33. |  |